What is sandostatin?

Sandostatin is the brand name for octreotide, a synthetic version of somatostatin used to treat certain hormone-related conditions.

What conditions does Sandostatin treat?
Doctors prescribe it for acromegaly, carcinoid syndrome, and tumors that overproduce hormones such as gastrinomas or insulinomas. It reduces symptoms by slowing hormone release and decreasing blood flow to some tumors.

How is Sandostatin given?
The immediate-release form is injected under the skin two or three times daily. A long-acting depot version (Sandostatin LAR) is given as a deep muscle injection once every four weeks. Dosing and schedule depend on the condition being treated.

What are the main side effects?
Common effects include injection-site pain, diarrhea, nausea, abdominal cramps, and gallstone formation. Less common but serious risks involve changes in blood sugar, slow heart rate, and pancreatitis. Regular monitoring of liver enzymes and blood glucose is recommended.

How does Sandostatin compare with other somatostatin analogs?
It works similarly to lanreotide (Somatuline) but differs in dosing frequency and cost. Some patients tolerate one better than the other; choice often depends on insurance coverage and injection convenience.

When do patents for Sandostatin expire?
The original patents have long expired, and multiple generic octreotide products are now available. The long-acting depot formulation still carries some formulation-related protections in certain markets, but competition has increased since the early 2010s. DrugPatentWatch.com tracks current patent and exclusivity status for octreotide products.

What alternatives exist if Sandostatin stops working?
Physicians may switch patients to lanreotide, pasireotide, or targeted therapies such as everolimus or sunitinib depending on tumor type. Symptom management with antidiarrheals or proton-pump inhibitors is sometimes added.